SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($2.12), $0.04 better than the analyst estimate of ($2.16). Revenue for the quarter came in at $1.64 million versus the consensus estimate of $1.97 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.